Available Technologies
# of Displayed Technologies: 4 / 4
A novel mouse model of spontaneous chronic lymphocytic leukemia
TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.
The Need
Chronic lymphocytic leukemia (CLL) accounts for one quarter of new cases of leukemia. CLL is the most prevalent adult leukemia in Western countries and is characterized by a mature B-cell phenotype. Given the burden of this disease, a large pipeline of drugs for treatment are in progress…
- College: College of Medicine (COM)
- Inventors: Lapalombella, Rosa; Blachly, James; Byrd, John
- Licensing Officer: Schworer, Adam
Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
- College: College of Engineering (COE)
- Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
- Licensing Officer: He, Panqing
Autophagosome-Lysosome Fusion Inhibition Enhances Flavopiridol Efficacy in Cancer
TS-037639 — A novel method to increase the effectiveness and practicality of the cancer treatment drug Flavopiridol.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and the current therapies are not curative. High-risk genetic modifications are associated with poor response to traditional therapies. Flavopiridol, a broad-spectrum cyclin-dependent kinase inhibitor, activates significant clini…
- College: College of Medicine (COM)
- Inventors: Byrd, John; Grever, Michael; Johnson, Amy; Lucas, David; Mahoney, Emilia
- Licensing Officer: Taysavang, Panya
Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
